Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments

被引:127
作者
Hong, SP
Kim, NK
Hwang, SG
Chung, HJ
Kim, S
Han, JH
Kim, HT
Rim, KS
Kang, MS
Yoo, W
Kim, SO
机构
[1] Pochon CHA Univ, Coll Med, Pundang CHA Gen Hosp, Inst Clin Med, Seongnam, South Korea
[2] Pochon CHA Univ, Coll Med, Pundang CHA Gen Hosp, Dept Internal Med, Seongnam, South Korea
[3] Pochon CHA Univ, Coll Med, Pundang CHA Gen Hosp, Dept Lab Med, Seongnam, South Korea
[4] Seoul Natl Univ, Coll Med, Canc Res Inst, GeneMatrix Inc, Seoul, South Korea
关键词
hepatitis B virus; lamivudine; YMDD variant; genotyping; mass spectrometry;
D O I
10.1016/j.jhep.2004.01.006
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Mutations in hepatitis B virus (HBV) to lamivudine resistance that arise during prolonged treatment frequently cause amino acid substitutions in the YMDD motif of HBV DNA polymerase. Current methods of detecting such variants are time-consuming, labor intensive, and unsuitable for screening large numbers of samples. Here, we describe the development of a matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS) genotyping assay suitable for detecting HBV variants in a sensitive and specific manner. Methods: The assay is based on PCR amplification and mass measurement of oligonucleotides containing sites of mutation of the YMDD motif. Results: The MALDI-TOF MS-based genotyping assay is sufficiently sensitive to detect as few as 100 copies of HBV genome per millilitre of serum, with superior specificity for determining mixtures of wild-type and variant viruses. When sera from 40 patients were analyzed, the MALDI-TOF MS-based assay correctly identified known viral variants and additional viral quasi-species not detected by previous methods, as well as their relative abundance. Conclusions: The sensitivity, accuracy and amenability to high-throughput analysis makes the MALDI-TOF MS-based assay suitable for mass screening of HBV infected patients receiving lamivudine, and can help provide further understanding of disease progression and response to therapy. (C) 2004 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:837 / 844
页数:8
相关论文
共 24 条
  • [1] Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions
    Aberle, SW
    Kletzmayr, J
    Watschinger, B
    Schmied, B
    Vetter, N
    Puchhammer-Stöckl, E
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (05) : 1972 - 1974
  • [2] Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B
    Ahmed, SNS
    Tavan, D
    Pichoud, C
    Berby, F
    Stuyver, L
    Johnson, M
    Merle, P
    Abidi, H
    Trépo, C
    Zoulim, F
    [J]. HEPATOLOGY, 2000, 32 (05) : 1078 - 1088
  • [3] Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine
    Allen, MI
    Gauthier, J
    DesLauriers, M
    Bourne, EJ
    Carrick, KM
    Baldanti, F
    Ross, LL
    Lutz, MW
    Condreay, LD
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (10) : 3338 - 3347
  • [4] Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
    Allen, MI
    Deslauriers, M
    Andrews, CW
    Tipples, GA
    Walters, KA
    Tyrrell, DLJ
    Brown, N
    Condreay, LD
    [J]. HEPATOLOGY, 1998, 27 (06) : 1670 - 1677
  • [5] Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
    Bartholomew, MM
    Jansen, RW
    Jeffers, LJ
    Reddy, KR
    Johnson, LC
    Bunzendahl, H
    Condreay, LD
    Tzakis, AG
    Schiff, ER
    Brown, NA
    [J]. LANCET, 1997, 349 (9044) : 20 - 22
  • [6] Cane PA, 1999, ANTIVIR THER, V4, P7
  • [7] Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
    Chayama, K
    Suzuki, Y
    Kobayashi, M
    Kobayashi, M
    Tsubota, A
    Hashimoto, M
    Miyano, Y
    Koike, H
    Kobayashi, M
    Koida, I
    Arase, Y
    Saitoh, S
    Murashima, N
    Ikeda, K
    Kumada, H
    [J]. HEPATOLOGY, 1998, 27 (06) : 1711 - 1716
  • [8] Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro
    Chen, RYM
    Edwards, R
    Shaw, T
    Colledge, D
    Delaney, WE
    Isom, H
    Bowden, S
    Desmond, P
    Locarnini, SA
    [J]. HEPATOLOGY, 2003, 37 (01) : 27 - 35
  • [9] Han JH, 2002, KOREAN J GENETIC, V24, P219
  • [10] Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment
    Kirishima, T
    Okanoue, T
    Daimon, Y
    Itoh, Y
    Nakamura, H
    Morita, A
    Toyama, T
    Minami, M
    [J]. JOURNAL OF HEPATOLOGY, 2002, 37 (02) : 259 - 265